Benzinga | Apr 29, 2021 07:51AM EDT

Endo Announces Qwo Data To Be Presented At The Aesthetic Meeting 2021 Apr. 30

Endo International plc (NASDAQ:ENDP) announced today that data relevant to the use of Endo Aesthetics' Qwo(r) (collagenase clostridium histolyticum-aaes), which received FDA approval in July 2020 for the treatment of moderate to severe cellulite in the buttocks of adult women, will be presented during The Aesthetic Meeting 2021.

This data will be highlighted in two oral presentations during the virtual and in-person meeting taking place in Miami, FL April 29--May 3, 2021.

* "Reduction in Dimple Volume in Women With Buttock Cellulite Treated With Collagenase Clostridium Histolyticum-aaes;" Lawrence Bass, M.D., medical director and founder, Bass Plastic Surgery, PLLC, and QWO clinical trial investigator; Sunday, May 2

* "Real-World Effectiveness and Safety of Collagenase Clostridium Histolyticum-aaes Injections for the Treatment of Thigh Cellulite in Women: An Interim Analysis;" Sachin Shridharani, M.D., F.A.C.S., founder, LUXURGERY(c),and QWO clinical trial investigator; Sunday, May 2

QWO will also be discussed during The Aesthetic Meeting's well-respected Premier Global Hot Topics program on Friday, April 30.